Roswell Park at ASH
December 6-9, 2025
Meet our experts at the 67th ASH Annual Meeting and Exposition!
Roswell Park Comprehensive Cancer Center will be present at the American Society of Hematology Conference (ASH) in Orlando, Florida from December 6-December 9, 2025. We invite you to meet with some of the experts in transplant and cellular therapy who are helping Roswell Park become a leading cellular therapy innovation engine!
Meet our doctors
Book a time to meet with us
Visit us at booth #2179 to meet members of our team, learn about our clinical trials, new approaches and our GMP Engineering and Cell Manufacturing Facility - the largest of its kind in the country.
Bridging the Gaps in Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access
Co-chairs: Marco Davila, MD, PhD, & Renier Brentjens, MD, PhD
Friday, December 5, 2025
3-6 p.m.
Chimeric antigen receptor (CAR) T-cell therapy has reshaped the treatment landscape for lymphoid & myeloid malignancies, yet major clinical and implementation challenges persist. This symposium addresses critical unmet needs in the field. This symposium will address critical unmet needs in the field, including optimization of CAR T-cells in real-world practice, managing post-relapse scenarios and expanding access to underserved populations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Roswell Park Comprehensive Cancer Center
Roswell Park presentations at ASH
Sunday, December 7th, 2025
- Dr. Marco Davila presenting abstract 558 - CAR T cell-driven induction of iNOS in tumor associated macrophages promotes CAR T cell resistance in B cell lymphoma
Monday, December 8th, 2025
- Dr. Megan Herr with senior author Theresa Hahn, PhD, Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor.
Sunday, December 7th, 2025
- Dr. Marco Davila presenting abstract 4098 - CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy
- Dr. Marco Davila presenting abstract 4141 - In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy induced toxicities in a clinical cohort
- Dr. Pamela Sung, presenting abstract 1488 - Combined FLT3 and EZH1/2 inhibition reduces LSCs and promotes myeloid differentiation in PDX models of AML.
- Dr. Ehsan Malek presenting - Accelerated Immune Aging After Induction Therapy in Multiple Myeloma Revealed by Donor-Referenced Immune Age Modeling.
Monday, December 8th, 2025
- Dr. Rahul Thakur, presenting abstract 6116 - Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features
- Jacob Wright, predoctoral researcher, with senior author Dr. Matthew Cortese, presenting abstract 5661 - Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)
- Dr. Allan Pavy, postdoctoral researcher, with senior author Dr. Marco Davila, abstract 5880 - IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma
- Dr. Sawyer Bawek, presenting - Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation.
- 6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study - Dr. Eunice Wang
- 3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL - Dr. Francisco Hernandez-Ilizaliturri
- 861 - Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™) - Dr. Francisco Hernandez-Ilizaliturri
- 111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study - Dr. Francisco Hernandez-Ilizaliturri & Dr. Alex Niu
- 72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study - Dr. Francisco Hernandez-Ilizaliturri
Delivering the next generation of cell & gene therapy
We invite you to transition your novel therapy concept into a tangible treatment poised for early phase clinical trials. Roswell Park's new GMP Engineering & Cell Manufacturing Facility offers secure production facilities and proven processes to seamlessly align the critical components of your project.
Be a part of our mission
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer
Join our Roswell Park faculty at these ASH receptions!
Late Night ASH Reception
Co-hosted by Dr. Philip McCarthy
Saturday, December 6, 2025
9 p.m.-2 a.m.
Blue Martini Point Orlando
9101 International Drive
Orlando, FL 32819
3rd Annual Football Party
Hosted by Dr. Renier Brentjens and Dr. Marco Davila
Sunday, December 7, 2025
3:30-8 p.m.
The Shark Bar at The Point
9101 International Drive, Suite 2200
Orlando, FL 32819
Physician resources
Our Physician Resources are by physicians for physicians – featuring educational videos with our experts to help keep you up to date on the latest research, treatments and innovations in cancer care
Roswell Park in the news
Keep up to date on our biggest innovations, clinical trials or groundbreaking work in our community in our Newsroom.